Rare Kidney Disease News

Targeting Inflammation and Fibrosis in IgA Nephropathy: Insights from the Phase 2 SPARTAN Study

Learn about clinical and biomarker findings from the Phase 2 SPARTAN trial in IgAN

Targeting Inflammation and Fibrosis in IgA Nephropathy: Preclinical Data and Translational Biomarker Insights

Explore inflammation and fibrosis in IgAN , preclinical sparsentan findings, and key urinary biomarkers

Sparsentan in IgAN: Spotlight on Phase 2 and OLE Clinical Trial Results Evaluating Concomitant Use With SGLT2i

Explore insights from the Phase 2 SPARTACUS trial, PROTECT OLE, and real-world data evaluating use of sparsentan with SGLT2i in IgAN

Engaging Patients for Better Outcomes: Informed Care for IgA Nephropathy

Access IgAN patient education resources, learn more about how IgAN develops, and explore advancements in IgAN care.

Exploring Clinical Trial Endpoints in FSGS: Spotlight on Proteinuria

Learn more about proteinuria as a primary clinical trial endpoint for focal segmental glomerulosclerosis studies.

Exploring the Mechanism of Sparsentan in IgAN: Including a Spotlight on Urinary sCD163, a Key Marker of Inflammation

Learn more about the role of u-sCD163 in IgAN and the biomarker findings from the SPARTAN interim analysis!